Sam Brusco, Associate Editor12.13.23
Integra LifeSciences has entered an agreement to acquire Acclarent from Ethicon—a Johnson & Johnson MedTech company—for $275 million in closing with further $5 million upon achievement of regulatory milestones.
Acclarent specializes in ENT (ear, nose, and throat) technologies and the acquisition positions Integra to be a key player in the ENT segment. Integra already touts its MicroFrance line of ENT instruments and Acclarent’s portfolio adds groundbreaking balloon technologies for sinus and eustachian tube dilation as well as surgical navigation systems.
Based in Irvine, Calif., Acclarent captures its revenues from U.S. sales, which reached $110 million in 2022. The company has R&D facilities in Irvine and Haifa, Israel. The company also utilizes third-party manufacturers.
“This acquisition presents Integra with a rare opportunity to become a key player in the ENT segment. Acclarent’s culture of pioneering technologies aligns with Integra’s legacy of innovation to transform care and restore patients’ lives,” said Jan De Witte, president and CEO of Integra. “We are looking forward to welcoming the Acclarent employees to the Integra team. Together, we can make a profound impact on the future of ENT and neurosurgery.”
“The ENT segment is an anatomical adjacency to neurosurgery. For example, this acquisition will provide opportunities for ENT and neurosurgeons to closely collaborate on tumor care using skull base approaches,” added Mike McBreen, president of the Codman Specialty Surgical division. “Acclarent’s strong commercial capabilities, R&D expertise, advanced portfolio and deep clinical knowledge will be important assets to Integra, allowing us to deliver future innovation not only within ENT, but also across our other CSS technology platforms.”
Acclarent specializes in ENT (ear, nose, and throat) technologies and the acquisition positions Integra to be a key player in the ENT segment. Integra already touts its MicroFrance line of ENT instruments and Acclarent’s portfolio adds groundbreaking balloon technologies for sinus and eustachian tube dilation as well as surgical navigation systems.
Based in Irvine, Calif., Acclarent captures its revenues from U.S. sales, which reached $110 million in 2022. The company has R&D facilities in Irvine and Haifa, Israel. The company also utilizes third-party manufacturers.
“This acquisition presents Integra with a rare opportunity to become a key player in the ENT segment. Acclarent’s culture of pioneering technologies aligns with Integra’s legacy of innovation to transform care and restore patients’ lives,” said Jan De Witte, president and CEO of Integra. “We are looking forward to welcoming the Acclarent employees to the Integra team. Together, we can make a profound impact on the future of ENT and neurosurgery.”
“The ENT segment is an anatomical adjacency to neurosurgery. For example, this acquisition will provide opportunities for ENT and neurosurgeons to closely collaborate on tumor care using skull base approaches,” added Mike McBreen, president of the Codman Specialty Surgical division. “Acclarent’s strong commercial capabilities, R&D expertise, advanced portfolio and deep clinical knowledge will be important assets to Integra, allowing us to deliver future innovation not only within ENT, but also across our other CSS technology platforms.”